financetom
Business
financetom
/
Business
/
Crescent Energy Among The 'Very Best' E&P Companies, Says Analyst: SilverBow Deal Offers 'Clear Synergies'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crescent Energy Among The 'Very Best' E&P Companies, Says Analyst: SilverBow Deal Offers 'Clear Synergies'
Jun 27, 2024 10:39 AM

Crescent Energy Co ( CRGY ) inked an agreement to acquire SilverBow Resources Inc ( SBOW ) for $2.1 billion.

While the company has been growing mainly through acquisitions, the purchase of SilverBow Resources ( SBOW ) "is the most impactful to date," according to KeyBanc Capital Markets.

The Crescent Energy ( CRGY ) Analyst: Tim Rezvan initiated coverage of Crescent Energy ( CRGY ) with an Overweight rating and price target of $16.

The Crescent Energy ( CRGY ) Thesis: The acquisition of SilverBow Resources ( SBOW ) will add to Crescent Energy's ( CRGY ) scale and production in the Eagle Ford, Rezvan said in the initiation note.

Check out other analyst stock ratings.

The purchase offers "clear synergies that can be attained, both financially (lower cost of capital, lower G&A/boe) and operationally (more simul-frac opportunities, best practices in the field and hydrocarbon optionality in the Eagle Ford)," the analyst wrote.

The 2025 estimates for Crescent Energy's ( CRGY ) free cash flow yield ranks "among the very best of any E&P company under coverage," Rezvan stated.

"The increased size of the Company, in addition to more high-quality inventory, warrants multiple expansion," he added.

CRGY Price Action: Shares of Crescent Energy ( CRGY ) had risen by 0.69% to $11.71 at the time of publication on Thursday.

Now Read:

Stock Of The Day: It’s No Coincidence CVS Health Stock Found Support Where It Did

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NIO Stock Is Sliding Thursday: What's Going On?
NIO Stock Is Sliding Thursday: What's Going On?
May 26, 2025
Shares of Chinese EV maker NIO Inc ( NIO ) – ADR fell around 3% to $4.00 on Thursday, tracking broader weakness in U.S.-listed Chinese stocks after Alibaba Group reported mixed fiscal fourth-quarter results. Alibaba shares dropped 8.1% to $123.05 after missing revenue expectations, despite beating earnings estimates. What To Know: Alibaba posted $32.58 billion in quarterly revenue, falling short...
Market Chatter: Thoma Bravo Sells Remaining Shares in Nasdaq
Market Chatter: Thoma Bravo Sells Remaining Shares in Nasdaq
May 26, 2025
12:20 PM EDT, 05/15/2025 (MT Newswires) -- Nasdaq (NDAQ) shareholder Thoma Bravo has divested its remaining approximately 43 million shares, around 7.4% of the company, in unregistered block trades for about $3.4 billion, Bloomberg reported Thursday, citing sources familiar with the matter. A Securities and Exchange Commission filing on May 9 showed that an affiliate of Thoma Bravo sold 17.3...
Oroco Resource Seeks Permission to Realign a River at its Santo Tomas Copper Project
Oroco Resource Seeks Permission to Realign a River at its Santo Tomas Copper Project
May 26, 2025
12:27 PM EDT, 05/15/2025 (MT Newswires) -- Oroco Resource ( ORRCF ) on Thursday said it is seeking regulatory permission for an expansion of its Santo Tomas project in Mexico and will look to move its share listing to the Toronto Stock Exchange. Oroco is seeking to shift a section of the river that runs adjacent to the Santo Tomas...
Eli Lilly, Rznomics Collaborate to Develop RNA-Editing Therapies for Hearing Loss Treatment
Eli Lilly, Rznomics Collaborate to Develop RNA-Editing Therapies for Hearing Loss Treatment
May 26, 2025
12:25 PM EDT, 05/15/2025 (MT Newswires) -- Eli Lilly ( LLY ) has signed a global research and licensing deal with South Korea-based Rznomics to develop RNA-editing therapies, Rznomics said in a statement Thursday. The partnership will use Rznomics' proprietary ribozyme platform to target treatments for sensorineural hearing loss. Rznomics will lead early-stage research, while Lilly will handle later-stage development...
Copyright 2023-2025 - www.financetom.com All Rights Reserved